RxDoctor Payments Data

Behrouz Dardashti, MD

Family Medicine · West Hills, CANPI 1275552705

Payments from drug & device makers

$1,594in general payments, 2019–2025

Across 49 payments — averaging $32.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$539
  • GSK$279
  • Amgen$164
  • Amarin Pharma, Inc.$148
  • Acadia Pharmaceuticals Inc$125
  • Telix Pharmaceuticals$105
  • plus $235 from 7 others

What the payments were for

  • Food & beverage$1,594100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,594 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$124,677
Medicare patients
320
Services billed
1,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$82,575
JardianceEmpagliflozin110$78,937
FarxigaDapagliflozin Propanediol55$56,194
VascepaIcosapent Ethyl43$25,193
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$20,546
JanuviaSitagliptin Phosphate37$20,408
RybelsusSemaglutide17$19,584
LinzessLinaclotide34$17,547
TradjentaLinagliptin58$16,708
MounjaroTirzepatide15$14,935
Diclofenac Sodium41$10,904
Breo ElliptaFluticasone/Vilanterol23$9,111
Icosapent Ethyl39$7,836
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,698
MyrbetriqMirabegron13$5,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$17$95,644168 claims
AstraZenecaFarxiga, Breztri Aerosphere$539$63,89366 claims
GSKTrelegy Ellipta, Breo Ellipta$279$29,65756 claims
Lilly USA, LLCMounjaro$25$14,93515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in West Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →